Thymosin Alpha-1 (Tα1) and Thymosin Beta 4 (Tβ4) are members of the thymosin peptide family originally isolated from thymic tissue. Despite sharing a common nomenclature, they differ fundamentally in mechanism, function, and clinical application. Tα1 is a potent immunomodulator, while Tβ4 drives tissue repair and regeneration.
- Sequence: 28 amino acids (SER-D-ALA-ALA-VAL-SER-THR-GLU-ASP-GLN-ILE-THR-THR-LYS-ASP-LEU-LYS-GLU-LYS-LYS-GLU-VAL-VAL-GLU-GLU-ALA-GLU-ASN-GLU)
- MW: 3,108 Da
- pI: ~4.2
- Disulfide bonds: None
- Source: Prothymosin α fragment (thymic tissue)
- Discovery: Goldstein and Low in 1977
- Sequence: 43 amino acids (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES)
- MW: 4,921 Da
- pI: ~5.2
- Disulfide bonds: None
- Source: Ubiquitous (found in all tissues)
- Discovery: Low and Goldstein in 1981
Tα1 activates multiple immune pathways:
- Dendritic cells: Enhances maturation, antigen presentation, and IL-12 production
- T cells: Promotes CD4+ and CD8+ differentiation, increases IFN-γ production
- NK cells: Enhances natural killer cell cytotoxicity
- Cytokine modulation: Shifts Th1/Th2 balance toward Th1
- TLR signaling: Activates TLR9, enhancing innate immunity
Tβ4 drives tissue repair through actin regulation and anti-inflammatory pathways:
- Actin polymerization: Sequesters G-actin, regulates cytoskeletal dynamics
- Cell migration: Promotes keratinocyte and endothelial cell migration
- Anti-inflammatory: Reduces IL-1β, TNF-α, NF-κB activation
- Angiogenesis: Promotes new blood vessel formation
- Stem cell mobilization: Supports tissue regeneration
| Property | Tα1 | Tβ4 |
|---|
| Primary receptor | TLR9 (innate immunity) | Actin cytoskeleton |
| Immune activation | Strong | Weak |
| Tissue repair | Weak | Strong |
| Cell migration | Minimal | Strong |
| Anti-inflammatory | Moderate | Strong |
| Angiogenesis | Minimal | Moderate |
| Application | Evidence Level | Key Findings |
|---|
| Hepatitis B | Phase III | 40% HBV DNA clearance vs 10% placebo |
| Hepatitis C | Phase II | Enhanced SVR when combined with IFN-α |
| HCC prevention | Phase III | Reduced recurrence after resection |
| Sepsis | Phase II | Improved survival in subgroup analysis |
| COVID-19 | Phase II/III | Reduced mortality in severe cases |
| Vaccination adjuvant | Phase II | Enhanced immune response to vaccines |
| Application | Evidence Level | Key Findings |
|---|
| Diabetic ulcers | Phase II | 50% faster healing vs placebo |
| Corneal wounds | Phase II | Reduced scarring, improved healing |
| Hair growth | Phase II | Increased hair density |
| Cardiac repair | Phase I | Improved ejection fraction post-MI |
| Wound healing | Preclinical | Accelerated closure in animal models |
| CNS repair | Preclinical | Promotes axonal growth |
| Parameter | Tα1 | Tβ4 |
|---|
| Half-life | ~2 hours | ~2 hours |
| Bioavailability (SC) | ~80% | ~70% |
| Tmax | 1–2 hours | 1–2 hours |
| Distribution | Primarily immune tissues | Ubiquitous |
| Metabolism | Proteolytic degradation | Proteolytic degradation |
| Dosing | 1.6 mg SC daily | 100–1000 µg (topical/injectable) |
| Indication | Dose | Route | Duration |
|---|
| Chronic hepatitis B | 1.6 mg | SC daily | 6–12 months |
| Hepatitis C adjunct | 1.6 mg | SC daily | 12 months |
| HCC prevention | 1.6 mg | SC daily | 12–24 months |
| COVID-19 | 1.6 mg | SC daily | 7–14 days |
| Vaccine adjuvant | 1.6 mg | SC | Single dose |
| Indication | Dose | Route | Duration |
|---|
| Diabetic ulcers | 100 µg/cm² | Topical daily | 4–12 weeks |
| Corneal wounds | 0.1% solution | Ocular TID | 2–4 weeks |
| Hair growth | 0.1% solution | Topical daily | 12–24 weeks |
| Wound healing | 100–500 µg | Topical daily | 4–8 weeks |
| Side Effect | Tα1 | Tβ4 |
|---|
| Injection site reactions | 5–10% | Rare (topical) |
| Fever | 2–5% | Rare |
| Fatigue | 2–5% | Rare |
| Headache | 1–3% | Rare |
| Allergic reactions | Rare | Rare |
| Systemic toxicity | None reported | None reported |
Both peptides have excellent safety profiles with minimal adverse effects.
| Category | Tα1 | Tβ4 |
|---|
| Clinical trials | 30+ (Phase I–III) | 10+ (Phase I–II) |
| FDA approval | Not approved (approved in China) | Not approved |
| Approved indications | Hepatitis B/C (China) | None |
| Preclinical studies | Extensive | Extensive |
| Safety database | Large (>10,000 patients) | Moderate (>1,000 patients) |
- Primary source: Thymic epithelium
- Plasma concentration: 1–10 nM
- Age-related changes: Declines with thymic involution
- Production: Prothymosin α → Tα1 processing
- Primary source: Ubiquitous (platelets, leukocytes, most tissues)
- Plasma concentration: 100–500 nM
- Age-related changes: Relatively stable
- Production: Constitutive expression
The combination could theoretically provide both immunomodulation and tissue repair:
- Wound healing: Tα1 for immune function + Tβ4 for repair
- Post-surgical: Tα1 for infection prevention + Tβ4 for tissue healing
- Chronic disease: Tα1 for immune support + Tβ4 for tissue maintenance
| Feature | Tα1 | Tβ4 |
|---|
| Size | 28 aa | 43 aa |
| MW | 3,108 Da | 4,921 Da |
| Primary function | Immunomodulation | Tissue repair |
| Mechanism | TLR9 activation, Th1 shift | Actin regulation, anti-inflammatory |
| Clinical stage | Phase III (hepatitis) | Phase II (wound healing) |
| Approved markets | China | None |
| Dosing | Injection (daily) | Topical or injection |
| Safety profile | Excellent | Excellent |
| Cost | Moderate | Low |
- Goldstein AL, et al. “Thymosin α1: isolation and characterization.” Proc Natl Acad Sci 1977;74:725-729.
- Low TLK, Goldstein AL. “Thymosin β4: purification and characterization.” J Biol Chem 1982;257:1000-1006.
- Li J, et al. “Thymosin α1 in viral infections.” Antiviral Res 2020;177:104761.
- Sosne G, et al. “Thymosin β4: wound healing and corneal repair.” Expert Opin Biol Ther 2012;12:373-388.
- Goldstein AL, et al. “Thymosin β4: a multi-functional regenerative peptide.” Expert Opin Biol Ther 2012;12:37-45.
